Trending Now
XS Services at 3-Month High Following Non-Core Asset Sale
If you think all cannabis stocks are crumbling, you’re not seeing Xtraction Services (CSE:XS). Shares of the Los Angeles-based specialty finance company...
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) Announces Its Intent to Purchase in...
The rapid spread of coronavirus has been a wakeup call for many pharmaceutical companies on how quickly they can make vaccines for emerging infectious...
The FDA Endorses a Phase 1/2 Clinical Trial of NT219 from...
Kitov Pharma (NASDAQ:KTOV) has had a successful journey in advancing its first-in-class therapies, which overcome tumor immune evasion. Its long-lasting treatments for people with...
Popular News
TG Therapeutics Inc. (NASDAQ:TGTX) Reports Phase 3 GENUINE Study Results Evaluating...
TG Therapeutics Inc. (NASDAQ:TGTX) has announced final GENUINE third Phase study results for the evaluation of ublituximab’s combination and ibrutinb relative to using ibrutinib...
MAKE IT MODERN
LATEST REVIEWS
Nabriva Therapeutics PLC – ADR (NASDAQ:NBRV) Receive The FDA’s Response After...
Nabriva Therapeutics PLC – ADR (NASDAQ:NBRV) recently announced that it received the Food and Drug Administration’s (FDA) complete response letter regarding its New Drug...
MAKE IT MODERN
PERFORMANCE TRAINING
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) CEO Presents Update On Mino-Lok Study At Life Sciences Investors...
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) has announced that its CEO Myron Holubiak will offer a virtual presentation at the Life Sciences Investors Forum, including an...
High-frequency trading during the holiday season
There always exists a conflict between investors and traders. One extracts inefficiencies in transactions while the other attempts to define value. Technological...
The FDA Endorses a Phase 1/2 Clinical Trial of NT219 from Kitov Pharma (NASDAQ:KTOV)
Kitov Pharma (NASDAQ:KTOV) has had a successful journey in advancing its first-in-class therapies, which overcome tumor immune evasion. Its long-lasting treatments for people with...
The Coronavirus Coping Portfolio (QDEL, GILD, QBIO, CYDY)
The COVID-19 pandemic has forced a dramatic realignment of social, cultural, and economic agendas because, in all cases, the healthcare issue has...
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) Finalizes RESOLVE-1 Third Phase Lenabasum Study In Systemic Sclerosis
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) has announced that the last subject in its RESOLVE-1 third phase lenabasum study for systemic sclerosis treatment has competed...
MAKE IT MODERN
POPULAR
